127 related articles for article (PubMed ID: 8471984)
1. A randomised trial of cyclophosphamide with and without low dose alpha-interferon in the treatment of newly diagnosed myeloma.
Aitchison R; Williams A; Schey S; Newland AC
Leuk Lymphoma; 1993 Feb; 9(3):243-6. PubMed ID: 8471984
[TBL] [Abstract][Full Text] [Related]
2. Maintenance treatment with interferon alpha-2b in multiple myeloma: a prospective randomized study from PETHEMA (Program for the Study and Treatment of Hematological Malignancies, Spanish Society of Hematology).
Bladé J; San Miguel JF; Escudero ML; Fontanillas M; Besalduch J; Gardella S; Arias J; García-Conde J; Carnero M; Marti JM; Rozman C; Estapé J; Montserrat E
Leukemia; 1998 Jul; 12(7):1144-8. PubMed ID: 9665202
[TBL] [Abstract][Full Text] [Related]
3. Interferon alfa-2b with VMCP compared to VMCP alone for induction and interferon alfa-2b compared to controls for remission maintenance in multiple myeloma: interim results.
Ludwig H; Cohen AM; Huber H; Nachbaur D; Jungi WF; Senn H; Günczler P; Schüller J; Eckhardt S; Seewann HL
Eur J Cancer; 1991; 27 Suppl 4():S40-5. PubMed ID: 1799476
[TBL] [Abstract][Full Text] [Related]
4. Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myeloma.
Oken MM; Kyle RA; Greipp PR; Kay NE; Tsiatis A; Gregory SA; Spiegel R J; O'Connell M J
Leuk Lymphoma; 1996 Feb; 20(5-6):447-52. PubMed ID: 8833401
[TBL] [Abstract][Full Text] [Related]
5. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA
Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521
[TBL] [Abstract][Full Text] [Related]
6. Recombinant interferon-alpha2b added to oral cyclophosphamide either as induction or maintenance in treatment-naive follicular lymphoma: final analysis of CALGB 8691.
Smith SM; Johnson J; Cheson BD; Canellos G; Petroni G; Oken M; Duggan D; Hurd D; Gockerman JP; Parker B; Prchal J; Peterson BA; ;
Leuk Lymphoma; 2009 Oct; 50(10):1606-17. PubMed ID: 19626540
[TBL] [Abstract][Full Text] [Related]
7. Interferon-alpha-2b with VMCP for induction in multiple myeloma: the Israel Myeloma Cooperative Group experience.
Cohen AM; Meytes D; Many A; Brenner B; Aghai E; Shaklai M; Kaufman S; Shtalrid M; Attias D; Manor Y
Isr J Med Sci; 1995 Oct; 31(10):604-10. PubMed ID: 7591683
[TBL] [Abstract][Full Text] [Related]
8. Australian Leukaemia Study Group myeloma II: a randomized trial of intensive combination chemotherapy with or without interferon in patients with myeloma.
Joshua DE; Penny R; Matthews JP; Laidlaw CR; Gibson J; Bradstock K; Wolf M; Goldstein D
Br J Haematol; 1997 Apr; 97(1):38-45. PubMed ID: 9136940
[TBL] [Abstract][Full Text] [Related]
9. A phase I trial of interferon-alpha-2a plus cyclophosphamide, vincristine, prednisone, and doxorubicin.
Schiller JH; Hawkins MJ; O'Connell MJ; Sielaff K; Borden EC
J Biol Response Mod; 1989 Jun; 8(3):252-61. PubMed ID: 2746297
[TBL] [Abstract][Full Text] [Related]
10. Experience with poorly myelosuppressive chemotherapy schedules for advanced myeloma. The Cooperative Group of Study and Treatment of Multiple Myeloma.
Brugnatelli S; Riccardi A; Ucci G; Mora O; Barbarano L; Piva N; Piccinini L; Bergonzi C; De Paoli A; Di Stasi M; Rinaldi E; Trotti G; Petrini M; Ascari E
Br J Cancer; 1996 Mar; 73(6):794-7. PubMed ID: 8611382
[TBL] [Abstract][Full Text] [Related]
11. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.
Salmon SE; Crowley JJ; Grogan TM; Finley P; Pugh RP; Barlogie B
J Clin Oncol; 1994 Nov; 12(11):2405-14. PubMed ID: 7964957
[TBL] [Abstract][Full Text] [Related]
12. Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization.
Arranz R; García-Alfonso P; Sobrino P; Zamora P; Carrión R; García-Laraña J; Pérez G; López J; Lavilla E; Lozano M; Rayón C; Colomer R; Barón MG; Flores E; Pérez-Manga G; Fernández-Rañada JM
J Clin Oncol; 1998 Apr; 16(4):1538-46. PubMed ID: 9580385
[TBL] [Abstract][Full Text] [Related]
13. Recombinant interferon-alpha 2b and high dose methyl prednisolone in relapsed and resistant multiple myeloma.
Ganjoo RK; Johnson PW; Evans ML; Williams A; Rohatiner AZ; Lister TA; Malpas JS
Hematol Oncol; 1993; 11(4):179-86. PubMed ID: 8144132
[TBL] [Abstract][Full Text] [Related]
14. Continuous prednisolone versus conventional prednisolone with VMCP-interferon-alpha2b as first-line chemotherapy in elderly patients with multiple myeloma.
Ludwig H; Spicka I; Klener P; Greil R; Adam Z; Gisslinger H; Tarkovács G; Linkesch W; Maniatis A; Morant R; Drach J; Kuhn I; Schuster J; Hinke A
Br J Haematol; 2005 Nov; 131(3):329-37. PubMed ID: 16225652
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II study of cyclophosphamide, carboplatin, and etoposide and autologous hematopoietic stem-cell transplantation with posttransplant interferon alfa-2b for patients with lymphoma and Hodgkin's disease.
Schenkein DP; Dixon P; Desforges JF; Berkman E; Erban JK; Ascensao JL; Miller KB
J Clin Oncol; 1994 Nov; 12(11):2423-31. PubMed ID: 7964959
[TBL] [Abstract][Full Text] [Related]
16. VMCP chemotherapy with or without interferon-alpha-2 in newly diagnosed patients with multiple myeloma.
Preis P; Scheithauer W; Fritz E; Zielinski C; Kuehrer I; Cortelezzi A; Polli E; Baldini L; Pirker R; Kriegisch A
Onkologie; 1989 Feb; 12(1):27-9. PubMed ID: 2654788
[TBL] [Abstract][Full Text] [Related]
17. Interferon therapy during the plateau phase of multiple myeloma: an update of the Swedish study.
Westin J; Cortelezzi A; Hjorth M; Rödjer S; Turesson I; Zador G
Eur J Cancer; 1991; 27 Suppl 4():S45-8. PubMed ID: 1799477
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of cyclophosphamide, doxorubicin, and 5-fluorouracil plus interferon-alpha 2b in patients with advanced breast cancer.
Sparano JA; Wadler S; Liebes L; Robert NJ; Schwartz EL; Dutcher JP
Cancer Res; 1993 Aug; 53(15):3509-12. PubMed ID: 8339255
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of multiple myeloma with high-dose chemotherapy and transplantation of autologous hematopoietic stem cells and subsequent maintenance therapy with interferon alfa-2b or interferon alfa 2b and dexamethasone. Report of the ongoing study of the "4W" Czech Myeloma Group].
Adam Z; Krejcí M; Bacovský J; Hejlová N; Kuca B; Svojgrová M; Franková H; Gumulec J; Janca J; Veprek K; Januska B; Lehanka F; Rezek Z; Praskac P; Cahová S; Vránová M; Papajík T; Králová E; Novotná J; Scudla V; Koza V; Drbal J; Faber E; Mareschová I; Hájek R
Vnitr Lek; 1998 Jul; 44(7):400-8. PubMed ID: 9748876
[TBL] [Abstract][Full Text] [Related]
20. Recombinant interferon alfa-2C versus polychemotherapy (VMCP) for treatment of multiple myeloma: a prospective randomized trial.
Ludwig H; Cortelezzi A; Scheithauer W; Van Camp BG; Kuzmits R; Fillet G; Peetermans M; Polli E; Flener R
Eur J Cancer Clin Oncol; 1986 Sep; 22(9):1111-6. PubMed ID: 3536528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
